Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 903094, 3 pages
http://dx.doi.org/10.1155/2013/903094
Case Report

Cell Based Autologous Immune Enhancement Therapy (AIET) after Radiotherapy in a Locally Advanced Carcinoma of the Cervix

1Chennai Meenakshi Multispeciality Hospital Limited, New No. 72, Old No. 148, Luz Church Road, Mylapore, Chennai 600 004, India
2Dr. Kamakshi Memorial Hospital, 1 Radial Road, Pallikaranai, Chennai 600100, India
3Nichi-In Centre for Regenerative Medicine (NCRM), PB 1262, Nungambakkam, Chennai 600034, India
4Biotherapy Institute of Japan, No. 8, No. 4 Edagawa 2-chome, Koto-ku, Tokyo 135-0051, Japan
5Hope Foundation (Trust), B6, 13, Zakariah Colony III Street, Choolaimedu, Chennai 600094, India
6School of Medicine, Yamanashi University, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan
7The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), PB 1262, Nungambakkam, Chennai, Tamil Nadu 600034, India

Received 16 February 2013; Accepted 19 March 2013

Academic Editors: K. Aogi, J. M. Buchanich, S. B. Chichareon, C. Gennatas, and F. A. Mauri

Copyright © 2013 Sumana Premkumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Radiotherapy is the primary form of treatment in patients with locally advanced cervical carcinoma. However for residual disease in the form of the persistent lymph nodes, surgery or chemotherapy is recommended. As surgery is not acceptable by every patient and chemotherapy has associated side effects, we hereby report the positive outcome of in vitro expanded natural killer cell and activated T lymphocyte based autologous immune enhancement therapy (AIET) for the residual lymphadenopathy in a patient with locally advanced cervical cancer after radiation. After six transfusions of AIET, there was complete resolution of residual lymph nodes and there was no evidence of local lesion. The patient also reported improvement in quality of life. As AIET has been reported as the least toxic among the available therapies for cancer, combining AIET with conventional forms of therapy in similar patients might not only improve the outcome but may also help the patients achieve a good quality of life.